Anti c jun nh2 terminal kinase jnk

NSCLC cell line A549 (Shanghai Institute of Cell Biology, China) was cultured in Roswell Park Memorial Institute (RPMI) Medium 1640 containing 10% fetal bovine serum (FBS, Gibco Corporation, Carlsbad, CA, USA), 1 mM glutamine, 1.5 g/L sodium bicarbonate, and 1% penicillin/streptomycin. Primary antibodies included anti-B-cell lymphoma-2 (Bcl-2), anti-BCL2-Associated X (Bax), anti-poly ADP ribose polymerase (PARP)-1, anti-myeloid cell leukemia 1 (Mcl-1), anti-Bcl-xL, anti-caspase-3, anti-caspase-8, anti-caspase-9 anti-PARP, anti-AMPK, anti-p-AMPK, anti-Akt, anti-p-Akt, anti-c-Jun, Phospho-c-jun (p-c-Jun), anti-c-Jun NH2-Terminal Kinase (JNK), anti-uncoordinated 51-like kinase 1 (ULK1), anti-p-JNK, anti-mTOR, anti-Beclin-1, anti-light chain 3 (LC3), anti-sequestosome 1 (p62) and anti-GAPDH, anti-DAPI, and anti-Tom20 were purchased from Cell Signaling Technology Inc (Beverly, MA, USA). Anti-cyclin A, anti-cyclin B2, anti-cyclin D1, anti-cyclin D3, anti-p21, and anti-Cdc2 were purchased from Sigma-Aldrich (Munich, Germany), as was analytical-grade NCTD.